Provenge Immunotherapy for Prostate Cancer 

Join Allan J. Pantuck, MD, MS, FACS, professor in the UCLA Department of Urology as he discusses the use of Provenge in the treatment of prostate cancer. Dr. Pantuck will discuss the background and rationale for the use of immune-based therapies in the treatment of cancer and the indications, benefits and side effects of Provenge, an FDA-approved treatment for advanced prostate cancer that utilizes the patient’s genetically engineered immune cells.

About Allan J. Pantuck, MD, MS, FACS

Dr. Pantuck is professor of urology at the David Geffen School of Medicine at UCLA, director of the Genitourinary Oncology Program at UCLA’s Jonsson Comprehensive Cancer Center, executive vice-chair of the UCLA Internal Review Board and a member of the Executive Committee of the UCLA Institute of Urologic Oncology.

Dr. Pantuck has received NIH funding for translational research in the development of molecular and genomic diagnostics for cancer and has 15 years’ experience in the design and implementation of gene and immune-based clinical trials. In addition to authoring several pending US patent applications, Dr. Pantuck has written more than 200 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.